Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda's Phase 3 G-HOPE-001 trial of TAK-921 met primary endpoints, showing significant overall and progression-free survival benefits in advanced gastric cancer. The results advance the drug toward regulatory filings in Asia.

Takeda (TAK) reported that its Phase 4 VERDICT trial showed ENTYVIO reduced UC complication risk by 67% in patients achieving disease clearance. The trial met its primary endpoint. TAK's stock is down 0.05% at $19.66.

Takeda Pharmaceutical (TAK, 4502.T) reported positive Phase 4 trial data for ENTYVIO in ulcerative colitis, showing disease clearance prolongs time to complications. The trial met its primary endpoint, reducing UC complication risk by nearly 70%. Results were presented at UEG Week 2026. Shares rose 0.36% in pre-market trading.

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.

Takeda reported Phase 4 VERDICT data showing ENTYVIO treat-to-target reduced UC complication risk by ~70% vs symptomatic remission alone (HR 0.33, P=0.0014). Safety data aligned with prior findings. The company suggests this reinforces ENTYVIO's role in moderate to severe UC treatment.

Takeda's ENTYVIO trial (VERDICT) showed treating ulcerative colitis to disease clearance (symptomatic, endoscopic, histologic remission) reduced complication risk by ~70% vs. symptomatic remission alone. Over 50% of patients achieved targets by Week 48. ENTYVIO's safety profile remained consistent with prior data. The study supports deeper remission goals for long-term disease control.